Newron Pharmaceuticals SpA (FRA:NP5) Short Interest


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
65 GF Score
Price €13.35
GF Value €13.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:NP5 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newron Pharmaceuticals SpA Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Short Interest distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Short Interest falls into.


FRA:NP5
65GF Score
Newron Pharmaceuticals SpA FRA:NP5
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.35 is trading 3.5% below its estimated GF Value™ of €13.83. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • Short Interest:
  • GF Value™: €13.83 vs. price of €13.35 (3.5% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
65GF Score

Get the complete analysis for FRA:NP5

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.35
Price
€13.83
GF Value